Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Teva- Pharmaceutical Industries Ltd. ADR’s stock clocked out at $16.40, down -2.50% from its previous closing price of $16.82. In other words, the price has decreased by -$2.50 from its previous closing price. On the day, 6.23 million shares were traded. TEVA stock price reached its highest trading level at $16.73 during the session, while it also had its lowest trading level at $16.32.
Ratios:
To gain a deeper understanding of TEVA’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.21 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.98. For the most recent quarter (mrq), Quick Ratio is recorded 0.61 and its Current Ratio is at 0.89. In the meantime, Its Debt-to-Equity ratio is 2.74 whereas as Long-Term Debt/Eq ratio is at 2.32.
On February 12, 2024, Piper Sandler Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $12 to $19.
Jefferies Upgraded its Hold to Buy on January 23, 2024, whereas the target price for the stock was revised from $10 to $14.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 18 ’24 when MIGNONE ROBERTO sold 519,000 shares for $17.03 per share. The transaction valued at 8,838,570 led to the insider holds 981,000 shares of the business.
Weiss Amir sold 12,635 shares of TEVA for $210,377 on May 16 ’24. The Chief Accounting Officer now owns 5,179 shares after completing the transaction at $16.65 per share. On May 15 ’24, another insider, Weiss Amir, who serves as the Chief Accounting Officer of the company, sold 15,500 shares for $16.80 each. As a result, the insider received 260,417 and left with 17,814 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TEVA now has a Market Capitalization of 18868529152 and an Enterprise Value of 35787304960. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.16 while its Price-to-Book (P/B) ratio in mrq is 2.55. Its current Enterprise Value per Revenue stands at 2.236 whereas that against EBITDA is 8.02.
Stock Price History:
Over the past 52 weeks, TEVA has reached a high of $17.69, while it has fallen to a 52-week low of $7.42. The 50-Day Moving Average of the stock is 2.14%, while the 200-Day Moving Average is calculated to be 32.24%.
Shares Statistics:
It appears that TEVA traded 9.99M shares on average per day over the past three months and 8769910 shares per day over the past ten days. A total of 1.13B shares are outstanding, with a floating share count of 1.13B. Insiders hold about 0.01% of the company’s shares, while institutions hold 52.74% stake in the company. Shares short for TEVA as of 1718323200 were 24563266 with a Short Ratio of 2.46, compared to 1715731200 on 12998935.
Dividends & Splits
The stock’s 5-year Average Dividend Yield is 2.95.
Earnings Estimates
The stock of Teva- Pharmaceutical Industries Ltd. ADR (TEVA) is currently in the spotlight, with 6.0 analysts actively rating and assessing its market standing.On average, analysts expect EPS of $0.56 for the current quarter, with a high estimate of $0.61 and a low estimate of $0.51, while EPS last year was $0.56. The consensus estimate for the next quarter is $0.64, with high estimates of $0.69 and low estimates of $0.6.
Analysts are recommending an EPS of between $2.67 and $1.34 for the fiscal current year, implying an average EPS of $2.34. EPS for the following year is $2.74, with 11.0 analysts recommending between $2.93 and $2.56.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $4.05B. There is a high estimate of $4.17B for the next quarter, whereas the lowest estimate is $4.01B.
A total of 10 analysts have provided revenue estimates for TEVA’s current fiscal year. The highest revenue estimate was $16.18B, while the lowest revenue estimate was $15.88B, resulting in an average revenue estimate of $16.02B. In the same quarter a year ago, actual revenue was $15.85BBased on 11 analysts’ estimates, the company’s revenue will be $16.61B in the next fiscal year. The high estimate is $17.01B and the low estimate is $16.23B.
